Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
585 Results for "
PD-L1
" in MedChemExpress (MCE) Product Catalog:
Products (585)
585 Results for "PD-L1" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-P99144A
Target:
Research Areas:
1
1
1 Cited Publications
Cat. No.: HY-19745A
CAS No.: 2310135-18-1
Target:
Research Areas:
N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.
1
Category:
Phyllodium pulchellum (L.) Desv. Phenols Polyphenols Plants Compositae Extract Disease Research Fields Cancer
Target:
1
1 Cited Publications
Cat. No.: HY-P10908
CAS No.: 3020015-02-2
Target:
Research Areas:
H-20 is a PD-1 agonist peptide. H-20 increases μOR mRNA in DRG neurons and modulates μOR-mediated analgesia. H-20 produces synergistic analgesic effects in inflammatory pain models and can reduce analgesic-induced tolerance, hyperalgesia, constipation, and motor impairment. H-20 can be used in pain-related research [1].
1
Target:
Research Areas:
1
1 Cited Publications
Research Areas:
HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .
1
Target:
Research Areas:
Cat. No.: HY-P10950A
Target:
Research Areas:
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy [1] .
Target:
Research Areas:
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 [1].
Target:
Research Areas:
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice [1].
Cat. No.: HY-P10950
CAS No.: 1931111-41-9
Target:
Research Areas:
Target:
Research Areas:
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research [1].
Cat. No.: HY-P2478
CAS No.: 2815311-61-4
Target:
Research Areas:
Cat. No.: HY-103048A
Purity: 99.34%
Target:
Research Areas:
Cat. No.: HY-168530
CAS No.: 3122200-59-0
Target:
Research Areas:
PDL1 degrader-1 is a palmatine-derived PD-L1 degrader. PDL1 degrader-1 interacts with and inhibits deubiquitinase CSN5, inducing PD-L1 Ub/proteasome-dependent degradation. PDL1 degrader-1 can be used for the research of non-small cell lung cancer [1].
Cat. No.: HY-P2477
CAS No.: 2135542-83-3
Target:
Research Areas:
Target:
Research Areas:
PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity [1].
Target:
Research Areas:
PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity [1].
Cat. No.: HY-162972
CAS No.: 2995357-09-8
Target:
Research Areas:
PROTAC PD-L1 degrader-2 is a PD-L1 PROTAC degrader with an IC50 of 197.4 nM and a Kd of 301 nM. PROTAC PD-L1 degrader-2 induces PD-L1 endocytosis, drives degradation via the proteasomal and lysosomal pathways, and inhibits the PD-1/PD-L1 interaction. As an immune activator, PROTAC PD-L1 degrader-2 increases the levels of CD4 +, CD8 +, granzyme B and perforin. PROTAC PD-L1 degrader-2 can be used in studies related to colon cancer immunology [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
